| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Simcere Zaiming, Inc. | 10%+ Owner | 20 ACORN PARK DR., CAMBRIDGE | Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer | 29 Sep 2025 | 0002080252 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 10%+ Owner | BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING, NANJING CITY, JIANGSU PROVINCE, CHINA | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact | 29 Sep 2025 | 0002082506 |
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | 10%+ Owner | NO 20, YAOGUYIHENG ROAD,, XIUYING DISTRICT, HAIKOU CITY, HAINAN PROVINCE, CHINA | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors | 29 Sep 2025 | 0002088064 |
| Simcere Pharmaceutical Group Ltd | 10%+ Owner | BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA | Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors | 29 Sep 2025 | 0002082516 |
| Ren Jinsheng | 10%+ Owner | BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA | Jinsheng Ren By: /s/ Jinsheng Ren | 29 Sep 2025 | 0001455397 |
| Tang Renhong | 10%+ Owner | BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA | Renhong Tang By: /s/ Renhong Tang | 29 Sep 2025 | 0002088593 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NXTC | Common Stock | 338,636 | 20 Jun 2025 | See footnotes | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons"). |
| F2 | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote. |
| F3 | The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| F4 | This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form. |
Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025